AUGUST 2012. Is a blend of dry botanical extracts, mixed in honey and date syrup. Each botanical extract has been authorized and defined by the Israeli.

Slides:



Advertisements
Similar presentations
GOLD MANAGEMENT PLAN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Advertisements

BY DR.Khaled Helmy Chest Specialist Al Mahmora Chest Hospital Ministry of Health - Egypt COPD SCOPE ON.
1 Pharmacy technician roles in helping clients with respiratory conditions.
Influenza Outbreaks and Cruise Ships Laura Martin 25 April 2002.
Drug Utilization Review (DUR)
PROBLEMS OF ASTHMA MANAGEMENT IN PAKISTAN. BURDEN OF ASTHMA ASTHMA IS ONE OF THE MOST COMMON CHRONIC DISEASE WORLDWIDE PREVALENCE INCREASING IN MANY COUNTRIES.
COPD Research at the University of Maryland School of Maryland COPD Clinical Research Center A member of the National Heart Lung & Blood Institute National.
ICS in COPD – A Risk Factor for CAP? Rate of pneumonia in ICS Studies
Lesson 4 Care and Problems of the Respiratory System Respiratory system problems can affect the functioning of other body systems. Imagine not being able.
Basma Y. Kentab MSc. Department of Clinical Pharmacy May 2014.
2.11 Conduct Medication Management University Medical Center Health System Lubbock, TX Jason Mills, PharmD, RPh Assistant Director of Pharmacy.
Identifying COPD in primary care: targeting patients at the highest risk What is COPD? Chronic obstructive pulmonary disease or COPD is a long-term inflammatory.
Tim Michels, Esq. IWIF.  When employees smoke, they are not the only ones who suffer the consequences  Increased medical costs, higher insurance rates,
Highly sensitive C-reactive protein levels in Iranian patients with pulmonary complications of sulfur mustard poisoning & its correlation with severity.
Dr. Danny Galdermans Dept Respiratory Medicine ZNA Middelheim Antwerp
Applied Epidemiology Epidemiology of Chronic Obstructive Pulmonary Disease (COPD) By Chris Callan 23 April 2008.
Bronchitis is one of the top conditions for which patients seek medical care.
CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD Juliana Tambellini University of Pittsburgh.
 Chronic obstructive pulmonary disease (COPD) is one of the most common lung disease  Makes it difficult to breathe  There are two main forms of COPD.
Meredith G. Hennon, MPH and the Supercourse team in Pittsburgh.
Drugs For Treating Asthma
Chronic Lower Respiratory Diseases. Two main Types Discussed Today Chronic Obstructive Pulmonary Disease (COPD) Asthma.
TOBACCO FACTS. IS IT REALLY WORTH IT???. WHAT DO THEY DO, AND HOW THEY ARE ADDICTING. Brain. * Nicotine, the drug that makes tobacco addictive, goes to.
Chronic Obstructive Pulmonary Disease Natasha Chowdhury.
Faculty Research Advisor: Dr. David Blake. Background Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide and.
BY MELISSA JAKUBOWSKI PULMONARY DISEASE TREATMENT CONCERNING COPD.
Paediatric Asthma Maria Tracey Paediatric Pharmacist Jane Davis Paediatric Clinical Nurse Specialist CF/Respiratory Royal Alexandra Hospital Paisley.
Approach to bronchiectasis
Section 1: Drugs Section 2: Drugs as Medicines Section 3: Drugs and the Brain.
Meeting the health needs of older drug users Dr Muriel Simmonte NHS Lothian Primary Care Facilitator Team/East Lothian Locality Drug Clinic.
Chronic Obstructive Pulmonary Disease
Daliresp (roflumilast) - Company: Forest Pharmaceuticals - Treatment for: chronic obstructive pulmonary disease (COPD). - First approved February 28th,
By: Hayley Allred, Courtney Zechman, and Amanda Guercioni.
Asthma exacerbations can be treated in multiple ways. Typically, an inhaled bronchodilator will be administered via nebulizer or MDI. Nebulizers have been.
-Cystic Fibrosis (CF) is one of the UK's most common life-threatening inherited diseases. -Cystic Fibrosis affects over 8,500 people in the UK. -Over.
By Dalia Munoz ASTHMA. is a serious and ongoing disease that affects the airways of both adults and children. Airways are the tubes that carry air in.
Hitetrapib – Eliminating Heart Disease Gillian Brazier Development Head, Cardiovascular Medicine.
Amber Kendall Jalisa Hendricks. Pathology:  A life-threatening disorder in which thick, sticky mucus builds up in the lugs, digestive tract, and other.
Effects of Smoking on Health Prepared by Amr Said Dahroug.
GOLD Update 2011 Rabab A. El Wahsh, MD. Lecturer of Chest Diseases and Tuberculosis Minoufiya University REVISED 2011.
The Association between blood glucose and length of hospital stay due to Acute COPD exacerbation Yusuf Kasirye, Melissa Simpson, Naren Epperla, Steven.
The Negative Impact of Air pollution on Respiratory Health Dr Des Murphy Consultant Respiratory Physician CUH.
COPD Diagnosis & Management Anil Ramineni Specialist Respiratory Physiotherapist Community Respiratory Team.
BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSIF General Features & Conditions to use antirheumatic Low doses are commonly used early in the course of the disease.
Exacerbations. Exacerbations An exacerbation of COPD is an acute event characterized by a worsening of the patient’s respiratory symptoms that is beyond.
Presented by: Bobbie Jo Bennett, Kristen Franklin, & Lacey McGallion
Disorders of the Respiratory System By : Amir Ashkan Ashrafian M.D.
Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.
ASTHMA MANAGEMENT AND PREVENTION PREFACE Asthma affects an estimated 300 million individuals worldwide. Serious global health problem affecting all age.
Asthma Guidelines, Diagnosis and Management Alison Hughes Respiratory Specialist Nurse Solent NHS Trust.
LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,
Dr Michelle Webb Renal Consultant, Associate Medical Director Patient Safety, East Kent Hospitals University NHS Foundation Trust and Co-lead for Sepsis.
ASTHMA Definition: Asthma is a chronic lung disease due to inflammation of the airways resulted into airway obstruction. The obstruction is reversible.
LSU Journal Club Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia A Systematic Review and Meta-analysis Scott Hebert,
Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.
The Impact of Asthma Education CHKV Medical Mission 2011 By Jo-Anne St. Vincent Jo-Anne St. Vincent.
Antibiotics in Addition to Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease Johannes M.A. Daniels; Dominic snijders;
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024Low Power Wide Area Network.
Prevention Diabetes.
A New Anti-inflammatory Therapy For COPD
Research where it is most needed National Respiratory Strategy
Community Health Pearl:
Prevention Diabetes Dr Abir Youssef 29/11/2018.
When Would You Use Single Inhaler Triple Therapy in COPD?
Asthma and COPD Hannah Bishop Advanced Nurse Practitioner
COPD Chronic Obstructive Lung Disease
E. Rand Sutherland, MD, MPH  Journal of Allergy and Clinical Immunology 
COPD Chronic Obstructive Lung Disease
Bronchitis Market is expected to grow at CAGR of 5.3% during the forecast period PREPARED BY Market Research Future (Part of Wantstats Research.
Presentation transcript:

AUGUST 2012

Is a blend of dry botanical extracts, mixed in honey and date syrup. Each botanical extract has been authorized and defined by the Israeli Ministry of Health and according to Pharmacists Regulation. The Soliair ™ has a patent pending PRODUCT DESCRIPTION

is a food supplement that contains a unique composition of ingredients, which has reported beneficial impact: 1. Honey - with antioxidant and antimicrobial effects dried botanical extracts with anti- inflammatory and antioxidant effects, along with potentiation of the immune system

can contribute to strengthening the respiratory system and may help patients in chronic respiratory diseases such as obstructive lung disease: PRODUCT BENEFITS COPD (chronic obstructive Disease of the airways usually caused by smoking) Asthma Bronchiectasis

COPD and asthma are common diseases: 5% of Americans over the age of 18 and 5-10% of Israelis are suffering or will suffer from COPD. It is estimated that 340 million people worldwide suffer from this disease. Estimates show that in Israel 2% of adults suffer from asthma. In the U.S. incidence of the disease in adults is close to 8%. Market Size and Potential

Therapy costs for COPD and its complications totaled in 2006 at $176.8 billion and are expected to rise to $389.2 billion by 2011 and to $832.9 billion by 2021 The Potential

Patients taking reported a decrease in seasonal infections of the respiratory tract. Reducing the incidence of respiratory infections benefit tremendous potential: Respiratory infections are an important factor in worsening the clinical course of chronic lung disease and increase the mortality of these diseases. The Potential cont.

Respiratory infections, including seasonal flu also damage the healthy young population; and has serious economic damage bearings due to absenteeism from work and school and a cause for hospital admissions. The Potential cont.

Current maintenance therapy includes a variety of medications taken (through inhalers); - Steroid drugs, which may cause local side effects (oral candidiasis, hoarseness) and in high doses - adverse systemic side effects. - Bronchodilators Conventional drug therapy for Obstructive lung diseases

During exacerbation events of COPD systemic administration of steroids is common. Such therapy carries significant side effects, such as salt retention and blood sugar elevation. Conventional drug therapy for Obstructive lung diseases

1. Has limited efficacy in patients with asthma and can not significantly inhibit the deterioration of respiratory function in patients with COPD and does not reduce disease exacerbations, hospitalization and mortality. 2. Causes side effects 3. Is expensive The Situation Today Conventional drug therapy

As far as we know, the supplement is free of side effects and has no interaction with conventional medication used for treatment of respiratory disorders.

מטופלמגדרגילהמחלהמשך\ גיל אבחון המחלה טפול תרופתי מינון התוסף זמן עד לשיפור 1נ'נ'70BOOP3 שניםסטרואידים חמצן 3 כפיות2 חודשים 2ז'ז'72asthmaילדותמשאף סטרואידי 3 כפיות1 חודש 3ז'ז'60COPD2 שניםמשאפים: מרחיבי סמפונות +\- סטרואיד 3 כפיות3 חודשים 4נ'נ'49asthmaילדותמשאף סטרואידי 3 כפיות1 חודש 5ז'ז'70 Diffuse lung dis. 3שניםהוצע טפול בסטרואידים 3 כפיות3 חודשים מדגם של 5 מטופלים

תפקודי נשימה של מטופלת מספר 4 17/2/0910/3/09

אוקטובר 2010 מאי 2008 חתכי CT חזה מקבילים של מטופל מספר 5 (סולי) לפני ואחרי נטילת SOLIAIR

פענוח בדיקת ה CT האחרונה של סולי

מכתב תודה של אחת המטופלות של סולי, המתאר שיפור במצבה לאחר נטילת SOLIAIR

מכתב תודה נוסף

Will commercialize the product Will team up with us to produce 2-3 applications Conduct a clinical research (if needed) Handle all the certification to sell the product Sell the product in Israel Export the product worldwide The Company is looking for a partner that